Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b

doi:10.3748/wjg.v23.i46.8120

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8565)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

443

WORD

266

HTML

4474

Figures (1-1)

188

Tables (1-3)

147

Sum=5518

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

608

Download

572

Sum=1180

Publishing Process of This Article

Item

Count

Browse

930

Download

937

Sum=1867

Dec 14, 2017 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Dec 14, 2017; 23(46): 8120-8127
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8120

Open in New Tab Full Size Figure Download Figure

Figure 1 Eradication of hepatitis C virus by interferon and direct-acting antiviral agents against hepatitis C virus. A: Interferon. Interferon induces interferon-stimulated genes (ISGs) transcription after binding its receptors and antiviral proteins. ISGs eradicate hepatitis C virus (HCV) with or without resistance associated substitutions (RASs) although interleukin-28B (IL28B) genotypes have an effect on its treatment results. B: direct-acting antiviral agents (DAAs) easily eradicate HCV without RASs because DAAs work in HCV sequence-specific manner. In some cases, it is difficult for DAAs to eradicate HCV with RASs.

Citation: Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127
URL: https://www.wjgnet.com/1007-9327/full/v23/i46/8120.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i46.8120